

HR 2480

CCM-CARE Act

Congress: 114 (2015–2017, Ended)

Chamber: House

Policy Area: Health

Introduced: May 20, 2015

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (May 22, 2015)

Official Text: https://www.congress.gov/bill/114th-congress/house-bill/2480

Sponsor

Name: Rep. Lujan, Ben Ray [D-NM-3]

Party: Democratic • State: NM • Chamber: Senate

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Lujan Grisham, Michelle [D-NM-1]	D · NM		May 20, 2015
Rep. Pearce, Stevan [R-NM-2]	R · NM		May 20, 2015

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	May 22, 2015

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
114 S 1391	Identical bill	May 20, 2015: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Cerebral Cavernous Malformations Clinical Awareness, Research, and Education Act of 2015 or the CCM-CARE Act

This bill amends the Public Health Service Act to require the National Institutes of Health (NIH) to strengthen and coordinate its efforts concerning cerebral cavernous malformation (CCM). (CCM is a condition in which blood vessels in the brain and spinal cord become enlarged, which can lead to seizures, paralysis, hearing or vision loss, or bleeding in the brain.) The NIH may award grants and enter into cooperative agreements for CCM research.

The NIH must: (1) award grants and contracts to plan and provide support for a network of CCM Clinical Research Centers; (2) identify and support additional centers to facilitate medical research to develop a cure for CCM and enhance medical care for CCM; and (3) convene a Cerebral Cavernous Malformations Research Consortium to develop programs for clinicians, scientists, and patients.

The Centers for Disease Control and Prevention may award grants and enter into cooperative agreements for the collection, analysis, and reporting of data on CCM.

The Department of Health and Human Services must award grants and enter into cooperative agreements for epidemiological activities related to CCM and must provide for a national CCM surveillance program.

The Food and Drug Administration must: (1) coordinate with clinical centers, investigators, and advocates to support investigational new drug applications in order to hasten clinical trials for CCM, and (2) support appropriate requests for designation of drugs for use in rare subpopulations of CCM patients as orphan drugs. (Orphan drugs are drugs developed to treat rare medical conditions and are eligible for certain incentives.)

Actions Timeline

- **May 22, 2015:** Referred to the Subcommittee on Health.
- **May 20, 2015:** Introduced in House
- **May 20, 2015:** Referred to the House Committee on Energy and Commerce.